Long Term Treatment of Herpes Simplex Encephalitis (HSE) With Valtrex

Condition(s) targeted: Encephalitis

Intervention: Placebo (Drug); Valacyclovir (Drug)

Phase: Phase 3

Status: Recruiting

Sponsored by: National Institute of Allergy and Infectious Diseases (NIAID)

Overall contact:
Ilet Dale, Phone: (205) 934-5316, Email: idale@peds.uab.edu

This study involves patients 12 years and older who have been diagnosed with Herpes Simplex Encephalitis (HSE) by a specific laboratory test and have completed treatment or are being treated with intravenous (given through a needle inserted into a vein) acyclovir. The purpose of the study is to determine if treatment with 4 tablets, 500 milligrams each, of valacyclovir given 3 times daily by mouth for 90 days is both effective and safe after completing intravenous acyclovir treatment and if it can increase survival with or without mild impairment of the brain and mental functions. Participants will be assigned to either drug or placebo (inactive substance) randomly (by chance). Study procedures will include blood samples and lumbar punctures (procedure in which a needle is inserted into the lower back to collect cerebral spinal fluid). Subjects will participate for up to 24 months.

Official title: A Phase III Double-Blind, Placebo-Controlled Trial of Long Term Therapy of Herpes Simplex Encephalitis (HSE): An Evaluation of Valacyclovir (CASG-204)

Study design: Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Efficacy Study

Primary outcome: Survival with no or mild neurological impairment after initiation of study medication, as measured by the Mattis Dementia Rating Scale (MDRS).

Secondary outcome:

Effect of study medication on quality of life measurements.

Survival with no or mild neurological impairment as measured by the MRDS, the Mini-Mental Status Examination, and the Glasgow Coma Scale.

Safety and tolerance of VACV administered at a dose of 2.0 grams given orally 3 times a day for 90 days.

Effect of antiviral therapy on HSV DNA in CSF (measured quantitatively by PCR).

Detailed description: Herpes simplex encephalitis (HSE) remains the most common cause of sporadic fatal encephalitis in the world. This study is a phase III, double-blind, placebo controlled study of long term therapy with valacyclovir as a treatment of herpes encephalitis. The primary objective of this study is to assess the impact of valacyclovir (VACV) therapy (following standard intravenous Acyclovir therapy) on neuropsychological impairment at one year post therapy, based on the cumulative scores of the Mattis Dementia Rating Scale (MDRS). The secondary objectives of the study are to: assess the effect of therapy on neuropsychological impairment at various time points; assess the effect of therapy on quality of life, based on the SF-36 Quality of Life Assessment; measure the effect of therapy on Herpes Simplex Virus (HSV) DNA in the cerebral spinal fluid (CSF); and assess the safety and tolerability of long term VACV therapy in patients with HSE. The tertiary objective of the study is to determine the frequency of symptomatic relapse/recurrence of HSE. Study participants will include 120 males and females, 12 years of age and older, diagnosed with HSE; laboratory confirmed CSF positive for HSV DNA by polymerase chain reaction (PCR). Consenting study participants will be randomized (1: 1) to either valacyclovir (active drug), 500 mg tablets, four tablets three times daily for 90 days or placebo (identical to active drug in appearance), 500 mg tablets, four tablets three times daily for 90 days. The primary endpoints of the study are to assess the impact of valacyclovir therapy [following standard intravenous Acyclovir (ACV) therapy] on neuropsychological impairment at one year post therapy and survival with no or mild neuropsychological impairment at 12 months after initiation of study medication, as measured by the MDRS. The secondary endpoints include: survival with no or mild neuropsychological impairment at 90 days and at 6, 12 and 24 months, as measured by the MDRS, the Mini-Mental Status Examination (MMSE), and the Glasgow Coma Scale; effect of study medication on quality of life measurements; effect of antiviral therapy on HSV DNA in CSF (measured quantitatively by PCR at Day 0 and Day 90); and safety and tolerance of VACV administered at a dose of 2. 0 grams given orally three times a day for 90 days. Tertiary endpoints include: frequency of symptomatic relapse/recurrence of HSE; survival with no or mild neuropsychological impairment at various time points, based on analysis of a disease-specific subset of questions from the test panel that measure frontal and/or temporal lobe dysfunction; survival with no or mild neuropsychological impairment at various time points assessed on an individual-subject basis using age, education, and IQ estimate, matched normative data for each subject as measured by the MDRS, MMSE, and tests of frontal/temporal lobe function; effect of antiviral therapy on HSV DNA in serum (measured quantitatively by PCR at clinical presentation, Day 0, and Day 90); and effect of antiviral therapy on HSV antibody in CSF as measured at clinical presentation, Day 0, and Day 90.

Minimum age: 12 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Informed consent and/or assent must be obtained from the patient or legal guardian.

- Patients with encephalopathy consistent with herpes simplex encephalitis (HSE) whose

cerebral spinal fluid (or brain biopsy sample) is positive for herpes simplex virus (HSV) deoxyribonucleic acid (DNA) by polymerase chain reaction (PCR).

NOTE: The purpose of this study is to assess patients with herpes simplex encephalitis, which is usually caused by HSV-1 and occasionally caused by HSV-2. A syndrome of HSV aseptic meningitis may also be encountered and is most often caused by HSV-2. HSV aseptic meningitis will result in a positive CSF PCR for HSV DNA. Investigators should not enroll subjects whose clinical and radiographic findings are suggestive of HSV meningitis without encephalitis. Investigators with questions about subject eligibility should contact one of the Protocol Chairs.

- Patients who are receiving and will have completed intravenous (IV) Acyclovir (ACV)

therapy for a minimum duration of 14 days to a maximum of 21 days and a minimum dose of 30 mg/kg/day to a maximum of 60 mg/kg/day, or equivalent dose as adjusted for renal dysfunction.

- Patient is expected to be available for follow-up visits of study drug administration

and through the 24 month study visit.

- Patients must be 12 years of age or older.

- Patient must weigh greater than or equal to 45. 5kg (100 pounds).

- All female patients with childbearing potential must have a negative pregnancy test

within 72 hours prior to initiation of study drug. If the pregnancy test is positive, the patient is ineligible for the study.

- Women must be post-menopausal, surgically sterile or willing to use adequate

contraception (barrier method with spermicide, intrauterine device (IUD), oral contraceptives, implant or other licensed hormone method) from time of study enrollment through 1 month after the last dose of study treatment.

- Men must be surgically sterile or willing to use contraception (barrier method with

spermicide) from time of study enrollment through 1 month after the last dose of study treatment.

Exclusion Criteria:

- Patients with herpes simplex virus (HSV) meningitis only, without evidence of HSV

encephalitis.

- Patients with an anticipated life expectancy <90 days.

- Patients with creatinine clearance of less than or equal to 50ml/min./1. 73m^2.

- Pregnant or breastfeeding females.

- Patients who have received any anti-herpesvirus medication (e. g. ganciclovir) other

than intravenous Acyclovir (ACV) for acute therapy of the current episode of herpes simplex encephalitis (HSE).

- Patients who are unable to swallow oral medications at the time of study drug

randomization (Day 0).

- Patients who are greater than 3 days beyond completion of treatment course with

intravenous (IV) ACV.

- Patients who are expected to receive long-term (>30days/year) therapy with antiviral

medications active against HSV [e. g. ACV, Valacyclovir (VACV), famciclovir).

Ilet Dale, Phone: (205) 934-5316, Email: idale@peds.uab.edu

Lund University, Lund, Sweden; Recruiting

Umea University, Umea, Sweden; Recruiting

Gothenberg University, Gothenberg, Sweden; Recruiting

Karolinska University, Stockholm, Sweden; Recruiting

Uppsala University Hospital, Uppsala, Sweden; Recruiting

Royal Free And University College Medical School, London NW3 2PF, United Kingdom; Recruiting

University of Alabama at Birmingham, Birmingham, Alabama 35294-2050, United States; Recruiting

University of Alberta, Edmonton, Alberta T6G 2B7, Canada; Terminated

St. Joseph's Hospital and Medical Center, Phoenix, Arizona 85013, United States; Recruiting

University of Southern California, Los Angeles, California 90033, United States; Terminated

University of California Davis Medical Center, Sacramento, California 95817, United States; Recruiting

University of Colorado, Denver, Colorado 80220, United States; Recruiting

The George Washington University Medical Center, Washington, District of Columbia 20037, United States; Terminated

Loyola University, Maywood, Illinois 60153, United States; Terminated

Indiana University, Indianapolis, Indiana 46202, United States; Terminated

University of Kansas Medical Center, Kansas City, Kansas 66160, United States; Recruiting

University of Kentucky, Lexington, Kentucky 40536, United States; Terminated

Tulane University, New Orleans, Louisiana 70112, United States; Suspended

University of Manitoba, Winnipeg, Manitoba R3E 0W3, Canada; Recruiting

Johns Hopkins University, Baltimore, Maryland 21287, United States; Recruiting

Mayo Clinic, Rochester, Minnesota 55905, United States; Recruiting

Saint Louis University, St. Louis, Missouri 63110-0250, United States; Active, not recruiting

University of New Mexico, Albuquerque, New Mexico 87131, United States; Recruiting

University of Toledo, Toledo, Ohio 43614, United States; Recruiting

Kingston General Hospital, Kingston, Ontario K7L 2V7, Canada; Recruiting

The University of Texas Health Science Center at Houston, Houston, Texas 77030, United States; Terminated

University of Virginia, Charlottesville, Virginia 22908, United States; Terminated

Starting date: September 2000
Ending date: July 2011
Last updated: February 12, 2009